Last reviewed · How we verify

Combination therapy with vigabatrin and prednisolone

Kullasate Sakpichaisakul · Phase 1 active Small molecule Quality 0/100

Combination therapy with vigabatrin and prednisolone is a Small molecule drug developed by Kullasate Sakpichaisakul. It is currently in Phase 1 development. Also known as: Sabril with prednisolone.

At a glance

Generic nameCombination therapy with vigabatrin and prednisolone
Also known asSabril with prednisolone
SponsorKullasate Sakpichaisakul
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Combination therapy with vigabatrin and prednisolone

What is Combination therapy with vigabatrin and prednisolone?

Combination therapy with vigabatrin and prednisolone is a Small molecule drug developed by Kullasate Sakpichaisakul.

Who makes Combination therapy with vigabatrin and prednisolone?

Combination therapy with vigabatrin and prednisolone is developed by Kullasate Sakpichaisakul (see full Kullasate Sakpichaisakul pipeline at /company/kullasate-sakpichaisakul).

Is Combination therapy with vigabatrin and prednisolone also known as anything else?

Combination therapy with vigabatrin and prednisolone is also known as Sabril with prednisolone.

What development phase is Combination therapy with vigabatrin and prednisolone in?

Combination therapy with vigabatrin and prednisolone is in Phase 1.

Related